3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Thrombocytopenia
7
Lymphoma, Non-Hodgkin
5
Neoplasms
3
Multiple Myeloma
3
Hodgkin Disease
3
Purpura, Thrombocytopenic, Idiopathic
2
Purpura, Thrombocytopenic
2
Ovarian Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Solid Tumor
1
Sarcoma, Ewing
1
Pancreatic Neoplasms
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Chemotherapy-induced Thrombocytopenia
1
Breast Neoplasms
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Bevacizumab
14
Cisplatin
12
Surveys and Questionnaires
11
Gemcitabine
9
Drug Therapy
9
Standard of Care
8
Nivolumab
7
Cetuximab
7
pembrolizumab
6
S 1 (combination)
6
Cyclophosphamide
6
atezolizumab
5
Specimen Handling
5
Endoscopic Mucosal Resection
5
Educational Status
5
Docetaxel
5
Blood Specimen Collection
5
fludarabine
4
aldesleukin
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
IFL protocol
4
Folfox protocol
4
Everolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Neoplasms
×
romiplostim
×
Clear all
NCT03362177
2026-02-11
RECITE
Amgen
Phase 3
Completed
165 enrolled
22 charts